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Summary
Pathogenesis of acute promyelocytic leukemia (APL) has been proposed to involve transcriptional repression through
enhanced corepressors binding onto RARA moieties of PML/RARA homodimers. Unexpectedly, we show that the K160
sumoylation site in the PML moiety of PML/RARA is required for efficient immortalization/differentiation arrest ex vivo,
implying that RARA homodimerization is insufficient to fully immortalize primary hematopoietic progenitor cells. Similarly,
PML/RARAK160R transgenic mice develop myeloproliferative syndromes, but never APL. The Daxx repressor no longer
binds PML/RARAK160R, but fusion of these two proteins restores the differentiation block ex vivo. Thus, transcriptional
repression dependent on a specific sumoylation site in PML is critical for the APL phenotype, while forced RARA dimeriza-
tion could control expansion of the myeloid compartment.S I G N I F I C A N C E
The PML/RARA oncogene initiates acute promyelocytic leukemia (APL) by repressing myeloid differentiation programs. Homodimer-
ization of PML/RARA triggers a tighter binding of RARA corepressors, which was proposed to account for transcriptional repression.
Sumoylation is a posttranslational modification of lysines often associated with acquisition of repression. We show that a specific
sumoylation site in PML is absolutely required for transformation ex vivo. In transgenic mice, expression of a PML/RARA mutant that
cannot undergo sumoylation induces myeloid hyperplasia, but never APL. This PML or PML/RARA sumoylation site allows the recruit-
ment of a potent repressor, Daxx. These results identify a repression domain in PML that controls the APL-specific differentiation
block, which could explain why PML is the most common fusion partner of RARA in APL.Introduction
Acute promyelocytic leukemia (APL) is initiated by the forma-
tion of a PML/RARA fusion protein (reviewed in Melnick and
Licht, 1999). Briefly, PML/RARA is a potent repressor, at least
in part through the ability of PML/RARA homodimers to recruit
and tightly bind nuclear receptor corepressors (Grignani et al.,
1998; He et al., 1998; Lin and Evans, 2000; Lin et al., 1998;
Minucci et al., 2000). The fusion protein also binds a much
larger set of response elements than the normal RARA/RXR
heterodimers, thus extending the transcriptional network nor-
mally controlled by this complex (Jansen et al., 1995; Kama-
shev et al., 2004; Perez et al., 1993). Both of these properties
rely on the presence of a strong dimerization/oligomerization
domain in PML (Kastner et al., 1992; Perez et al., 1993). Yet,
why PML, rather than any self-dimerizing protein, is the recur-
rent fusion partner of RARA in APL is not understood. One
possible clue stems from the localization of PML to specific
nuclear domains, PML nuclear bodies (NBs), which are dis-
rupted upon expression of PML/RARA. PML and NBs play a
role in the control of apoptosis or senescence, possibly
through modulation of P53 activation (Gottifredi and Prives,CANCER CELL : FEBRUARY 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER2001; Salomoni and Pandolfi, 2002). Indeed, PML/RARA ex-
pression induces a sharp resistance to apoptosis (Grignani et
al., 1993; Wang et al., 1998). Nuclear bodies are structures
where PML recruits a variety of proteins, including the Daxx
repressor (Li et al., 2000). PML-triggered recruitment/seque-
stration of Daxx away from the chromatin could account for
the fact that PML modulates transcription (Lehembre et al.,
2001; Li et al., 2000; Zhong et al., 2000b). Conversely, when
PML is artificially tethered to DNA, its interaction with Daxx
may account for repression (Vallian et al., 1997; Wu et al.,
2001).
Sumoylation is a posttranslational modification that tags a
ubiquitin-like peptide, SUMO, onto specific lysine residues.
Sumoylation appears to modulate tertiary structure, protein/
protein interactions, and subcellular localization. Despite the
large number of proteins that may be sumoylated, there are
only a few examples where loss of a specific sumoylation site
has yielded clear functional changes ex vivo, except for tran-
scription factors whose sumoylation is often associated with
the acquisition of transcriptional repression (Verger et al.,
2003). PML sumoylation is required for the recruitment of part-
ner proteins such as Daxx or Sp100, but not for NB formationINC. DOI 10.1016/j.ccr.2005.01.005 143
A R T I C L Eor nuclear matrix targeting (Ishov et al., 1999; Lallemand-
Breitenbach et al., 2001; Zhong et al., 2000a). There are three
sumoylation sites within PML (Kamitani et al., 1998), but only
K160 is required for arsenic-triggered PML or PML/RARA de-
gradation, most likely through its ability to recruit the 11S pro-
teasome (Lallemand-Breitenbach et al., 2001; Zhu et al., 1997).
This specific lysine was also implicated in PML degradation by
viral proteins (Boutell et al., 2003).
Transcriptional repression is central to the pathogenesis of
APL, as shown by the sensitivity of the disease to HDAC inhibi-
tors (He et al., 2001; Warrell et al., 1998). In the current view of
APL pathogenesis, PML/RARA homodimers repress the ex-
pression of target genes. Indeed, a variety of RARA-fusion pro-
teins are associated with rare or exceptional forms of human
APL, and all of these RARA partners (PLZF, NPM/B23, STAT5b,
NuMA) harbor strong homodimerization domains (Piazza et al.,
2001). Any direct contribution of PML to PML/RARA-induced
transcriptional repression is unclear, and why PML is the most
common RARA partner remains unsettled. Here, we have ad-
dressed the role of PML sumoylation in PML/RARA transforma-
tion both in vivo and ex vivo.
Results
To examine the role of PML/RARA sumoylation in APL patho-
genesis, we expressed PML/RARA or the PML/RARAK160R
mutant in mouse primary hematopoietic precursor cells. After
transduction and growth/selection in methylcellulose, PML/
RARA-expressing cells are highly immature by immunopheno-
typing (Du et al., 1999). In contrast, PML/RARAK160R expres-
sion reproducibly yields differentiation profiles that are interme-
diate between those induced by expression of PML/RARA and
empty vector (Figures 1A and 1B). Granulocytes were found on
cytological preparations of vector-transduced cells, blasts, and
promyelocytes in those expressing PML/RARA, but PML/
RARAK160R-transduced cells displayed features of activated
macrophages. PML/RARA-transduced cells can be indefinitely
replated in methylcellulose. In contrast, PML/RARAK160R-
expressing cells could only be replated twice, demonstrating
that defective sumoylation impairs PML/RARA-dependent im-
mortalization (Figure 1C). Similarly, PML/RARA-transformed
cells consistently grew faster in liquid culture than those trans-
duced with PML/RARAK160R (Figure 1D). Transduced cells ex-
pressed similar levels of PML/RARA or PML/RARAK160R, al-
though, as previously shown (Lallemand-Breitenbach et al.,
2001), several sumoylated forms of PML/RARA were absent
from the mutant (Figure 1E). Note that, in these primary cells
(including human APL cells), up to half of the total amount of
the fusion protein is SUMO-conjugated. Thus, a critical sumoy-
lation site in the PML moiety of PML/RARA is required for com-
plete differentiation block and immortalization of primary
hematopoietic precursor cells.
Transcriptional repression induced by forced RARA dimeriza-
tion was proposed to underlie the pathogenesis of APL (Lin
and Evans, 2000; Minucci et al., 2000). We thus examined
whether the K160 sumoylation site would alter PML/RARA di-
merization, DNA binding, or enhanced corepressor associa-
tion. PML/RARAK160R retains the ability to impair retinoic acid
response in transient transfection assays in SaOS2 cells (Fig-
ure 2A), although a modest, but consistent, decrease in basal
PML/RARA-dependent transcriptional repression was observed.144Similar results were obtained in Cos or 293T cells (data not
shown). The ability of PML/RARAK160R to bind PML or RXR
(Figures 2B and 3A) or to disrupt PML nuclear bodies was un-
affected by this mutation (Figure 2C). Finally, using the DR5
response element from the RARB gene, we found that PML/
RARAK160R behaved exactly as PML/RARA with respect to
its ability to bind DNA as a homodimer or to display an en-
hanced affinity for the SMRT corepressor (Figure 2D). Altoge-
ther, these results show that PML/RARAK160R exerts very
similar properties as PML/RARA as regards dimerization, core-
pressor binding, repression of RA-target genes, PML binding,
and nuclear body disruption, but fails to significantly impair dif-
ferentiation of primary hematopoietic progenitors. These ob-
servations therefore imply that the APL differentiation block is
not solely due to enhanced binding of corepressors onto PML/
RARA homodimers and is not properly reflected by transcrip-
tional repression of retinoic acid target genes in transient trans-
fections.
We have recently shown that in APL cells, PML/RARA is
mostly complexed to RXR and hence can bind DNA in a variety
of manners (e.g., as PML/RARA homodimers, [PML/RARA-
RXR]2 tetramers, or PML/RARA-RXR heterodimers [Kamashev
et al., 2004]). In vivo, the K160R mutation might favor the for-
mation of PML/RARA-RXR heterodimers, which would not ex-
hibit enhanced SMRT binding. To directly demonstrate that
RARA homodimers are insufficient to trigger differentiation ar-
rest, we introduced in the RARA moiety of PML/RARAK160R
two mutations previously shown to abolish RXR binding (Zhu
et al., 1999), which hence force PML/RARA to bind DNA as
a homodimer (Figure 3A). The double mutant PML/RAR-
AK160R,M883R,T886R protein homodimerizes on DNA, binds
the SMRT corepressor tightly, and still represses transcription
from retinoic acid-sensitive reporters (Figures 3A and 3B). Yet,
its expression in primary hematopoietic progenitor cells only
induces a minor differentiation arrest and fails to immortalize
cells, behaving essentially as PML/RARAK160R (Figures 3C
and 3D). The PML/RARAK160R,M883R,T886R protein is more
stable than PML/RARA (data not shown) and remains monosu-
moylated, but otherwise displays the classical microspeckled
nuclear distribution characteristic for the fusion protein (Daniel
et al., 1993) (Figure 3E). Note that the M883R,T886R mutation
alone enhances, rather than impairs, the differentiation block
induced by PML/RARA (Figures 3C and 3D). This experiment
directly demonstrates that RARA homodimerization, as seen in
PML/RARAK160R homodimers, is not sufficient to trigger full
differentiation arrest and the immortalization of primary mouse
hematopoietic progenitor cells.
To explore the significance of these observations in an in
vivo setting, we generated transgenic mice expressing PML/
RARA or nls-PML/RARAK160R under the control of the MRP8
promoter (Brown et al., 1997). Development of APL in MPR8-
PML/RARA transgenic mice has been extensively described
previously and shown to occur with an incomplete penetrance
(Brown et al., 1997, Kogan et al., 2001). Transgenic mice with
high PML/RARA expression develop a skin disease (Hansen et
al., 2003), which precludes their reproduction. Mouse APL cells
are transplantable to unirradiated syngenic recipients, and
transplantation of prediseased transgenic bone marrow suf-
fices to recapitulate leukemia development in the host, demon-
strating that the disease is cell-autonomous. Similar ranges of
expression of these two constructs were obtained (data notCANCER CELL : FEBRUARY 2005
A R T I C L EFigure 1. Comparison of primary hematopoietic precursors transduced by PML/RARA or PML/RARAK160R
A: Flow cytometry analysis of c-Kit, Gr1, and Mac1 in vector-, PML/RARA-, or PML/RARAK160R-transduced cells.
B: MGG stained cytospins of cells analyzed in A.
C: Serial replating in methylcellulose.
D: Comparison of the growth rates in liquid culture. Mean of 3 different experiments.
E: Western blot analysis of PML/RARA and PML/RARAK160R in transduced cells. The position of SUMO-modified PML/RARA proteins is indicated. As previously
shown (Lallemand-Breitenbach et al., 2001), the K160 site is required for multiple sumoylation events.shown) and only lines that express the fusion protein were con-
sidered for the study. A full account of the animal data is pre-
sented in Supplemental Table S1. We first examined the F1
progeny: in 2 of 3 PML/RARA lines, offspring developed sple-
nomegaly at 22 and 23 months. Similarly, all of the 7 nls-PML/
RARAK160R founders with progeny had at least 1 offspring
(but up to 5) with splenomegaly, with a similar mean latency of
21 months (Supplemental Table S1, Figure 4A). In both PML/
RARA and nls-PML/RARAK160R transgenics with splenomeg-
aly, an increase in blood and marrow neutrophils, with a corre-
sponding decrease in lymphocytes, was consistently found
(data not shown), as previously reported in transgenic mice ex-
pressing other APL-associated fusion proteins (Sukhai et al.,
2004). While splenomegaly due to splenic hematopoiesis was
observed (Supplemental Table S1), extramedullar hematopoie-
sis was not observed in the livers, which remained of normal
aspect on macroscopic examination. Thus, the K160R muta-
tion does not abolish the ability of the PML/RARA transgene
to initiate myeloid expansion.
Bone marrows from all F0 founders were engrafted into irra-
diated syngenic recipients, allowing the analysis of all trans-
genic lines, including those that had failed to reproduce. Sim-
ilar to the F1 offspring, grafts from 5 of 8 PML/RARA founders
developed splenomegaly with a mean latency of 13 months
(including the time from donor birth to transplantation). Grafts
from 4 of 10 nls-PML/RARAK160R founders also developed
splenomegaly (mean latency 20 months), demonstrating that
bone marrows expressing nls-PML/RARAK160R retain theCANCER CELL : FEBRUARY 2005ability to promote myeloid expansion upon engraftment (Figure
4B and Supplemental Table S1). Importantly, cytological analy-
sis of the bone marrow demonstrated variable degrees of block
in granulocytic differentiation in PML/RARA mice, in contrast
to those derived from nls-PML/RARAK160R mice (data not
shown). Similarly, the preleukemic marrow from PML/RARA
mouse 26 could be replated at least 6 times, while 4 different
marrows from PML/RARAK160R mice with splenomegaly
never replated more than twice (data not shown), consistent
with the ex vivo transduction data. To confirm these differences
in myeloid differentiation, the hyperplastic marrows from F0
grafts were retransplanted into irradiated syngenic hosts.
Transplantation greatly enhanced the differentiation block in
PML/RARA mice, since 4 of 5 lines rapidly developed morpho-
logically typical APL, on average 4 months after retransplanta-
tion (Supplemental Table S1, Figure 4B). Histologic examina-
tion reveals multiorgan invasion of blast cells (Figure 4C and
data not shown). Very high numbers of APL blasts were present
in the blood (Figure 4D). The bone marrow blasts are highly
homogenous, have typical promyelocytic morphology, and ex-
press both immature markers (c-Kit and ScaI) and, at interme-
diate levels, some myeloid markers (Mac and GR) (Figures 4C
and 4E), reflecting the proliferation of immature myeloid cells.
Hemoglobin levels were normal and platelet counts low (data
not shown). These APL are very aggressive malignancies that
kill all recipients, irradiated or not, with very short latencies
(Figure 4B) and, as expected, were retinoic acid- and arsenic-
sensitive (data not shown). In sharp contrast, none of the hy-145
A R T I C L EFigure 2. PML/RARAK160R shares all known features of PML/RARA
A: Transcriptional response to RA of vector-, PML/RARA-, or PML/RARAK160R-transfected SaOS2 cells.
B: PML similarly binds PML/RARA and PML/RARAK160R. PR, PML/RARA homodimers; PRS, PML/RARA-SMRT complex.
C: Immunofluorescence analysis (PML antibody) of primary hematopoietic cells, demonstrating that the K160R mutation does not change the microspeck-
led pattern of the fusion protein (Daniel et al., 1993).
D: Retinoic acid similarly regulates SMRT//PML/RARA interactions in gel-shift analysis.perplastic bone marrows derived from nls-PML/RARAK160R
ever evolved toward APL, despite an extended followup (Sup-
plemental Table S1 and Figure 4B). Rather, the recipients of
secondary grafts from nls-PML/RARAK160R bone marrows
developed splenomegaly at low penetrance after a long lat-
ency, in irradiated animals only (Figure 4B and data not shown).
Bone marrows from these animals were hyperplastic (Figure
4C), and contained more myeloid cells than marrows derived
from control animals (Figures 4D and 4E), but exhibited neither
a morphological differentiation block nor the appearance of im-
mature cells on the immunophenotype. Multiorgan invasion
was not observed (Figure 4C). Similarly, in the two PML/RARA
lines whose offspring (but not F0 grafts) developed splenomeg-
aly, F1 bone marrows also rapidly yielded APL upon en-
graftment (Supplemental Table S1), while, again, none of the
bone marrows grafted using nls-PML/RARAK160R F1 offspring
as donors ever yielded APL (Supplemental Table S1). Altoge-
ther, of the 8 PML/RARA founder lines, 6 eventually yielded
APL from either F0 or F1 grafts, while APL was never detected
in any of the grafts from hyperplastic bone marrows derived
from the 10 nls-PML/RARAK160R founder lines (Supplemental
Table S1 and Figure 4F).
The nls tag does not alter any of the known properties of
PML/RARA, and transduction of PML/RARAK160R or nls-PML/
RARAK160R in primary mouse hematopoietic cells induced146similar incomplete differentiation block. Nevertheless, to con-
firm our results, we generated a second set of PML/RARAK160R
transgenics. To date, 8 of 9 transgenic mouse lines developed
a dense hyperplastic bone marrow, including two lines with
splenomegaly without myeloid differentiation block in second-
ary grafts (Supplemental Table S1). All other findings (skin dis-
ease, shift toward myeloid markers in bone marrow immuno-
phenotyping) in this second group of PML/RARAK160R mice
were identical to the first set (Supplemental Table S1 and data
not shown). We thus conclude that the K160R mutation does
not block PML/RARA-induced myeloproliferation, but that this
sumoylation site contributes to the APL-specific differentiation
block and disease aggressiveness, fully consistent with the ex
vivo data.
Upon sumoylation of its 3 conjugation sites, PML recruits a
number of proteins, including Sp100, Daxx, and the 11S pro-
teasome (Ishov et al., 1999; Lallemand-Breitenbach et al.,
2001; Zhong et al., 2000a). As Daxx is a potent and promiscu-
ous repressor involved in PML-dependent modulation of tran-
scription, we focused on the role of K160 in PML/Daxx interac-
tions. Mutation of PML K160 completely abolished recruitment
of Daxx onto PML bodies and also precludes Daxx recruitment
toward the APL-specific microspeckles upon PML/RARAK160R
expression (Figure 5A), further establishing the critical role of
this specific sumoylation site in the recruitment of PML-associ-CANCER CELL : FEBRUARY 2005
A R T I C L EFigure 3. Forced homodimerization of PML/RARA does not induce differentiation arrest or immortalization
A mutation that abolishes RXR binding (M883R, T886R) was introduced in PML/RARA or PML/RARAK160R to enforce homodimer formation; SMRT binding
(A), transcriptional activation (B), immunophenotyping (C), replating assays (D), and morphology, immunofluorescence, and Western blot (E) were per-
formed as described above. In A, PR denotes the PML/RARA dimer; PRS, its complex with the SMRT corepressor; and PRX, the PML/RARA//RXR tetramer.ated proteins (Lallemand-Breitenbach et al., 2001). In contrast,
mutation of the other major sumoylation site, K490, does not
affect the ability of PML to recruit Daxx onto PML bodies (data
not shown). Similarly, yeast two-hybrid experiments demon-
strated that Daxx could efficiently repress transcription of the
His gene to which PML was tethered by a Gal4-PML fusion
(Figure 5B). Note that the yeast strain used in these experi-
ments grows on histidine-less media, as some basal transcrip-
tion of the His gene occurs prior to Gal4-dependent transcrip-
tional activation. PML/Daxx interaction results in growth arrest,
presumably as a consequence of Daxx-induced His silencing,
while Daxx expression does not block growth in the absence
of Gal4-PML expression (Figure 5B). Strikingly, Daxx failed to
block yeast growth in the presence of GAL4-PMLK160R (Fig-
ures 5B and 5C). A similar role of K160 was found when PML/
RARA was fused to the GAL4 DNA binding domain, except
that some repression of His gene expression was already notedCANCER CELL : FEBRUARY 2005upon expression of PML/RARA. Similarly, mammalian two-
hybrid also showed that tethering of PML or PMLK160R to the
promoter of a luciferase reporter gene impairs its activity (Li et
al., 2000; Vallian et al., 1997; Wu et al., 2001), demonstrating
that PML contains sequences implicated in transcriptional re-
pression, apart from the K160 sumoylation site. Coexpression
of Daxx further represses luciferase expression in the presence
of PML, but not PMLK160R (Figure 5D). Altogether, these re-
sults establish that K160 is the critical residue in PML impli-
cated in the recruitment of Daxx, resulting in transcriptional si-
lencing.
Recruitment of Daxx onto PML/RARA should trigger tran-
scriptional repression of PML/RARA targets, but, in addition,
PML/RARA may also titrate Daxx off its chromatin binding sites
and could hence enhance expression of Daxx-responsive
genes (Kim et al., 2003; Lehembre et al., 2001; Li et al., 2000;
Lin et al., 2003). We undertook a set of experiments to clarify147
A R T I C L EFigure 4. Characterization of PML/RARA and nls-PML/RARAK160R transgenics
A: Incidence of myeloproliferation/splenomegaly in the 7 lines of nls-PML/RARAK160R transgenics with offspring. Each founder line was scored positive on
a date corresponding to the average latency required for splenomegaly development in the offspring.
B: Bone marrows of F0 founders were serially grafted in irradiated (green arrow) or unirradiated (blue arrow) syngenic recipient mice. All reported mice,
except 30, showed splenomegaly at the first necropsy (green dot). Graft 2 for mouse 30 is shown by an open circle. Upon secondary grafts, bone marrows
derived from PML/RARA mice rapidly developed APL (red dot), while those derived from nls-PML/RARAK160R mice only showed a late recurrence of
myeloid hyperplasia in a fraction of the recipients. Note that APLs are aggressive acute leukemias that kill all recipient mice, irradiated or unirradiated.
C: Bone marrow cytology and marrow and liver histology of mice with APL (PML/RARA) or myeloproliferation (nls-PML/RARAK160R).
D: Blood counts of normal, PML/RARA, or nls-PML/RARAK160R grafts at the time they develop APL or splenomegaly with myeloproliferation. WBC, white
blood cells; N, neutrophils; L, lymphocytes; M, monocytes; E, eosinophils; Bla, blasts. Means and standard deviations are taken from at least 3 animals of
different lines.
E: Immunophenotypes of bone marrow cells of normal mice (control), or mice with APL (PML/RARA) or myeloproliferation (nls-PML/RARAK160R).
F: Summary of the fate of the bone marrows derived from the different F0 or F1 transgenic upon serial transplantation.148 CANCER CELL : FEBRUARY 2005
A R T I C L EFigure 5. PML/RARA-triggered transformation is associated with recruitment of the Daxx repressor
A: Daxx localization in PML- or PMLK160R-expressing fibroblasts (top) and in PML/RARA-or PML/RARAK160R-expressing hematopoietic precursors (bottom)
derived from PML−/− mice.
B: Yeast two-hybrid experiments demonstrating that repression of the His locus requires the PML/Daxx interaction, which depends on K160 for both PML
and PML/RARA.
C: Schematic representation of the two-hybrid repression experiments in B.
D: Mammalian double hybrid demonstrating that the PML/Daxx interaction requires K160.
E: Flow cytometry analysis of Mac1 or c-Kit expression in hematopoietic precursor cells transduced with vector, PML/RARA, PML/RARAK160R, POZ-PML/
RARAK160R, or Daxx-PML/RARAK160R.
F: Serial replating assays of PML/RARAK160R- and Daxx-PML/RARAK160R-transduced cells.CANCER CELL : FEBRUARY 2005 149
A R T I C L Ethe role of Daxx recruitment in cells transformation. As ex-
pected, transduction of PML/RARAK490R yields cells indistin-
guishable from PML/RARA-transformed ones (data not
shown). Coexpression of PML/RARA and Daxx triggers essen-
tially the same features as that of PML/RARA alone, which
does not favor a role of PML/RARA to titrate Daxx off its other
DNA binding sites (data not shown). In contrast, fusion to the
N terminus of PML/RARAK160R of two distinct repression do-
mains (either the C terminus of Daxx [Hollenbach et al., 1999]
or the POZ domain of PLZF PLZF [Dong et al., 1996]) restores
all the features of cells transformed ex vivo by PML/RARA. No-
tably, Kit expression (Figure 5E), promyelocyte-specific differ-
entiation arrest, and continued replating up to the 7th passage
(Figure 5F and not shown) were all restored, strongly suggest-
ing that the function lost by the PML/RARAK160R mutant is its
ability to fully repress transcription. In contrast, fusion of Daxx
to RARA did not trigger differentiation arrest or immortalization
ex vivo (data not shown), strongly suggesting that enforced
homodimerization of RARA fusions contributes to these pro-
cesses. Direct fusion of SUMO-1 or SUMO-2 to the N terminus
of PML/RARAK160R allows one further round of replating,
but yields cells with an immunophenotype similar to PML/
RARAK160R (data not shown), pointing to the importance of
position-specific sumoylation for the differentiation block. Alto-
gether, these results very strongly suggest that the function lost
in PML/RARAK160R is transcriptional repression, likely result-
ing from Daxx recruitment onto the PML/RARA-RXR com-
plexes.
Discussion
Combination of PML-mediated RARA homodimerization, en-
hanced corepressor binding, and repression of RA target genes
was proposed to trigger the APL-specific differentiation block
(Lin and Evans, 2000; Minucci et al., 2000). Probing PML/RARA
function in primary hematopoietic progenitor cells demon-
strates that RARA homodimerization is insufficient to initiate
APL, as PML/RARA mutants that efficiently dimerize and tightly
bind corepressors do not fully impair differentiation or immor-
talize these cells ex vivo and were incapable of initiating APL
in mice. The PML/ RARAM883R,T886R mutant also directly
demonstrates that titration of RXR (Kastner et al., 1992) does
not make an important contribution to the APL phenotype, at
least ex vivo. In contrast, the K160 sumoylation site appears
to be critical for the differentiation block ex vivo and APL devel-
opment in vivo, although it does not enhance the association
of nuclear receptor corepressors. Restoration of the differentia-
tion block through fusion of PML/RARAK160R to several dis-
tinct repression domains strongly suggests that the function
lost upon mutation of K160 is the ability of the fusion to alter
transcription of target genes. Surprisingly, such loss of K160-
dependant transcriptional repression is not easily detected
when probing PML/RARA function by transient transfections
using RA-sensitive reporters. PML/RARA sumoylation could al-
low the fusion to permanently silence target genes, for example
through histone and DNA methylation (Di Croce et al., 2002).
Daxx was indeed proposed to bind the DNA-methylase-asso-
ciated protein DMAP-1 (Muromoto et al., 2004), which might
explain why the consequences of the K160 mutation were al-
ways more visible in stable expression systems than in tran-
sient assays (Figures 5B and 5D). Interestingly, experiments in
Xenopus oocytes had shown that RARA-associated corepres-150sors and histone deacetylases cannot fully account for PML/
RARA-dependent repression and nucleosome reorganization
(Segalla et al., 2003). RARA homodimerization alone (as ob-
served in PML/RARAK160R) is insufficient to trigger a full APL
phenotype. Yet, that the Daxx-RARA fusion did not alter differ-
entiation or induce self-renewal of primary hematopoietic cells
strongly suggests that enforced RARA dimerization neverthe-
less makes an important contribution to these processes. Di-
merization could be important through enhanced SMRT bind-
ing (implying a dual, nonredundant, contribution of the two
repression domains to transformation, Figure 6) and/or by ex-
tending the repertoire of DNA binding sites and hence the
number of target genes (Kamashev et al., 2004).
To our knowledge, we have identified the first setting where
SUMO-dependant repression controls transformation ex vivo
and where any sumoylation mutant has an in vivo phenotype.
We cannot formally rule out the possibility that K160 is the
target of other posttranslational modifications (ubiquitination,
isgylation, acetylation, methylation, etc.), but the fact that it is
a well-characterized sumoylation site (Kamitani et al., 1998),
previously implicated in arsenic-enhanced PML sumoylation by
SUMO-1 and -2 (Lallemand-Breitenbach et al., 2001), as well
as SUMO-dependent recruitment of partner proteins onto
nuclear bodies (Lallemand-Breitenbach et al., 2001) (Figure 5),
does not favor this hypothesis. For a large number of transcrip-
tion factors, sumoylation was shown to induce repression
through the recruitment of a variety of interacting proteins
(Verger et al., 2003). For example, sumoylation enhances the
ability of PLZF (the other recurrent RARA fusion partner) to re-Figure 6. A model for APL pathogenesis and response to targeted ther-
apies
PML/RARA, dimerized, but also bound to RXR (Kamashev et al., 2004), binds
one or two SMRT molecules, resulting in transcriptional repression (blue ar-
row) that is released by RA (red arrow). In a symmetrical manner, the K160
sumoylation site recruits Daxx, resulting in strong repression (blue arrow).
Arsenic trioxide (red arrow) modulates the sumoylation of lysine 160 in PML/
RARA (Lallemand-Breitenbach et al., 2001), which could modulate Daxx
binding prior to PML/RARA catabolism (Zhu et al., 1997). Protein interfaces
critical for transformation and targeted by the therapies are shown in red.CANCER CELL : FEBRUARY 2005
A R T I C L Epress expression of its target genes (Kang et al., 2003). Tran-
scriptional repression could be due to Daxx recruitment, since
this potent repressor interacts with PML/RARA in a strictly
K160-dependent manner (Figure 5). Similarly, SUMO-depen-
dant recruitment of Daxx onto Smad4 was very recently shown
to account for transcriptional repression (Chang et al., 2005).
Yet, in our situation, attempts to directly implicate Daxx in
the differentiation arrest, using lentiviral expression of Daxx
SiRNA, failed, because Daxx downregulation triggered apopto-
sis (Michaelson et al., 1999; Michaelson and Leder, 2003).
Identification of a critical repression function in the PML moiety
of PML/RARA, as previously seen with the POZ domain in the
PLZF moiety of variant PLZF/RARA fusions (Grignani et al.,
1998; He et al., 1998; Lin et al., 1998), points to t(15,17) APL
as yet another example of myeloid leukemias where the trans-
location fuses a potent repression domain to a heterologous
DNA binding domain (Rabbitts, 1994) (Figure 6). This likely ex-
plains why PML, rather that any self-dimerizing protein, is the
most common RARA partner in APL.
PML/RARAK160R transgenic mice never developed APL,
but rather myeloproliferations. In that respect, when expressed
in mice, other APL-associated RARA-fusions (PLZF/RARA,
NuMA/RARA, NPM/RARA) also trigger myeloproliferation with-
out maturation defects, rather than typical APL (Cheng et al.,
1999; He et al., 1997; Sukhai et al., 2004), stressing the impor-
tance of the PML moiety of the fusion to trigger the promyelo-
cytic differentiation block (Bernardi et al., 2002). Enhanced co-
repressor binding on PML/RARA homodimers could underlie
the myeloid hyperplasia observed in PML/RARAK160R trans-
genic mice. That PML/RARA sumoylation controls the differen-
tiation block, but not the expansion of myelopoiesis in vivo,
implies that distinct sets of target genes control these two
functions. Interestingly, the normal RARA gene was previously
implicated in both stem cell expansion (Purton et al., 2000) and
granulocytic differentiation (Kastner et al., 2001). Molecular
profiling of gene expression in progenitor cells expressing
PML/RARA or its sumoylation mutant may allow the dissection
of the pathways that control these two features of APL cells.
Our observations identify an unanticipated symmetry in the
determinants for RA and arsenic response within PML/RARA
(Figure 6). Either of the two agents triggers rapid degradation
of PML/RARA through the respective targeting of the PML (ar-
senic) or RARA (RA) moieties of the fusion (Zhu et al., 1997,
1999, 2001). At the molecular level, the determinant of RA re-
sponse is the AF2 activation domain in RARA, which is impli-
cated in transcriptional repression, RA-dependent transactiva-
tion, and receptor degradation (Zhu et al., 1999). Accordingly,
mutations in this region of PML/RARA have been associated
with RA resistance, through both enhanced transcriptional re-
pression and absence of RA-triggered PML/RARA degradation
(Cote et al., 2000; Duprez et al., 2000; Shao et al., 1997; Zhou
et al., 2002). Similarly, the K160 sumoylation site in the PML
moiety of the fusion is required for transcriptional repression
and transformation, but also for arsenic-modulated sumoyla-
tion and PML or PML/RARA degradation (Lallemand-Breiten-
bach et al., 2001; Zhu et al., 1997), which may raise new
hypotheses as to the mechanism(s) of arsenic action in APL
(Zhu et al., 2002).
Experimental procedures
Retroviral transduction and cell analyses
The cDNA encoding PML/RARA corresponds to the bcr1 breakpoint and
includes the alternatively spliced exon 5 as well as the PML nls (de Thé etCANCER CELL : FEBRUARY 2005al., 1991). The encoded PML/RARA fusion protein hence contains all 3 PML
sumoylation sites. The PML/RARAK160R mutant was described elsewhere
(Lallemand-Breitenbach et al., 2001). The C terminus of Daxx (aa 575–740),
containing the major repression domain (Hollenbach et al., 1999) or the
N-terminal POZ domain of PLZF (Dong et al., 1996; Li et al., 1997), was
fused in-frame to the N terminus of PML/RARAK160R. Similarly, SUMO-1
or -2 (kindly provided by R. Yeh) were fused in-frame to the N or C terminus
of PML/RARAK160R. The two mutations that abolish RXR binding to RARA
were transferred from RARAM380R/T383R into PML/RARA (Zhu et al.,
1999).
Infection of lineage-depleted bone marrow from 5-fluorouracil-treated
C57BL/6 mice and culture and G418 selection of the transduced progeni-
tors cells in methylcellulose with stem cell factor, IL3, IL6, and GM-CSF
were performed as described (Du et al., 1999). After a week, neomycin-
selected cells were recovered from methylcellulose and either analyzed
(FACS, MGG staining, immunofluorescence, and Western blot) or replated
at a density of 10,000 cells/dish. Cells were serially replated until they
stopped growing. Affinity-purified anti-PML rabbit or hen sera were used
for immunofluorescence and Western blotting. Cell growth was assessed in
RPMI 1640 medium supplemented with 10% fetal calf serum and the same
cytokines, except GM-CSF.
Transgenic mice
PML/RARA was expressed using the MRP8 promoter (Brown et al., 1997)
in B6/CBA F1 hybrids. Hematological disorders such as splenomegaly were
not observed in nontransgenic littermates. The K160 mutation was intro-
duced into the transgene with an SV40 nls tag (11 transgenics, 39-month
followup) or without (9 transgenics, 24-month followup). Only transgenics
lines expressing the fusion proteins by both Western blot and immuno-
fluorescence are reported here (8/8 for PML/RARA, 10/11 nls-PML/
RARAK160R, 9/9 PML/RARAK160R). For the sake of simplicity, mice that
had “acute myeloid leukemia with features of human acute promyelocytic
leukemia” are described as having “APL” (Kogan et al., 2002). Myelopro-
liferation was defined by the association of splenomegaly (spleen larger
than 160 mg) with highly hyperplastic marrow, in the absence of significant
differentiation abnormalities. Several founders developed a severe skin dis-
ease precluding their reproduction (Hansen et al., 2003), and some founders
gave no progeny. F0 founders were sacrificed and phenotypes were ob-
served in offspring (when available) or primary grafts in irradiated syngenic
recipients. The second graft was used to demonstrate (or not) rapid pro-
gression from preleukemia to full-blown APL. Founder lines were scored
positive for APL or myeloproliferation on the average time required to de-
velop a phenotype, taking in account the time spent since birth of the donor
bone marrow in the case of grafts. Blood cell counts were performed with
a Celldyn 3700 counter from Abbot diagnosis. Bone marrow and pathology
analyses were performed as before (Lallemand-Breitenbach et al., 1999).
Reporter assays and yeast double hybrid
SaOS2, COS, or 293T cells were transiently cotransfected with indicated
constructs (20 ng expression vector, 100 ng RARE3-tk-Luc reporter [de Thé
et al., 1990], and 100 ng of tk-renilla control vector). Cells were treated with
RA (10−6 M) or vehicle, overnight. For yeast two-hybrid assays, we used
the strain HF7c (Clontech) carrying His as reporter gene. PML, PMLK160R,
PML/RARA, or PML/RARAK160R were cloned in the yeast expression vec-
tor pBridge (Clontech) carrying the GAL4 DNA binding domain (DBD) and
the selective Trp gene. A cDNA encoding the complete hDaxx gene was
cloned in the yeast vector pGADGH (Clontech) carrying, or not, the GAL4
activator domain (AD) and the selective Leu gene. Transfections were per-
formed using the lithium acetate method, and yeast strains were grown in
appropriate selective medium as drop-out Trp/Leu or drop-out Trp/Leu/His
media. Mammalian two-hybrid was performed as described using vectors
kindly provided by A. Zelent (Chester Beaty Laboratories, London), where
PML was expressed as a fusion protein with the GAL4 DNA binding domain
and a luciferase expression vector under the control of GAL4 binding sites.
Analysis of the properties of transduced proteins
Electrophoretic shift analyses were performed as previously described (Zhu
et al., 1999), using extracts from Cos-transfected cells and a bacterially
expressed SMRT fragment (He et al., 1998). Immortalized PML−/− mouse
embryo fibroblasts (Quignon et al., 1998) were infected by retroviruses ex-151
A R T I C L Epressing various PML derivatives (Lallemand-Breitenbach et al., 2001). The
subnuclear localization of endogenous mouse Daxx protein was analyzed
using an anti-Daxx antibody (Hollenbach et al., 1999).
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/2/143/DC1/.
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